For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Alkermes, Inc.

USPTO Granted Patents = 75

CIPO Patents = 11

EPO Patents = 20

Trademarks = 21

Forward Citations = 2,935

Loading Chart...

Loading Chart...

95 inventors (with patents filed for the assignee):

Juan C Alvarez (11 out of 15 patents)

Steven G Wright (10 out of 42 patents)

J Michael Ramstack (8 out of 44 patents)

4. Joyce M Hotz (8 out of 30 patents)

5. Phillip M Friden (8 out of 13 patents)

6. Nathan Oliver Fuller (7 out of 11 patents)

7. Lewis D Pennington (7 out of 20 patents)

8. Michael E Rickey (7 out of 31 patents)

9. John Adams Lowe, Iii (7 out of 83 patents)

10. Shawn L Lyons (6 out of 28 patents)

11. Rajesh Kumar (6 out of 14 patents)

12. Demetri Theodore Moustakas (5 out of 8 patents)

13. Brian M Aquila (5 out of 27 patents)

14. Hoan Huynh (5 out of 10 patents)

15. Roman A Valiulin (5 out of 8 patents)

Core Competencies:

Substituted Piperidino Compounds

Histone Deacetylase Inhibitors

IL-10 Modulation

Pain Treatment Compounds

Single Chain Fc Fusion Proteins

Peripherally Acting Opioid Compounds

Selective Opioid Compounds

Naltrexone Formulations

Pulmonary Drug Delivery

Sustained Release Devices

Microencapsulated Compounds

Inhalation Devices

75 patents: Sort by Forward Citations

1. 12441710 - Substituted piperidino compounds and related methods of treatment (2025-10-14),

2. 12054495 - Substituted macrocyclic compounds and related methods of treatment (2024-08-06),

3. 12006330 - Substituted macrocyclic compounds and related methods of treatment (2024-06-11),

4. 11987580 - Bicyclic inhibitors of histone deacetylase (2024-05-21),

5. 11912702 - Substituted pyridines as inhibitors of histone deacetylase (2024-02-27),

6. 11858939 - Hetero-halo inhibitors of histone deacetylase (2024-01-02),

7. 11760747 - Substituted piperidino compounds and related methods of treatment (2023-09-19),

8. 11542276 - Substituted macrocyclic compounds and related methods of treatment (2023-01-03),

9. 11534480 - Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties (2022-12-27),

10. 11286256 - Bicyclic inhibitors of histone deacetylase (2022-03-29),

11. 11225479 - Bicyclic inhibitors of histone deacetylase (2022-01-18),

12. 11225475 - Substituted pyridines as inhibitors of histone deacetylase (2022-01-18),

13. 11180455 - Compounds for the treatment of pain (2021-11-23),

14. 10919902 - Hetero-halo inhibitors of histone deacetylase (2021-02-16),

15. 10881741 - Single chain Fc fusion proteins (2021-01-05),

Alkermes, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative medicines for the treatment of central nervous system (CNS) disorders. With a focus on addressing unmet patient needs, Alkermes combines its deep scientific expertise, proprietary technologies, and strategic partnerships to deliver novel therapeutic solutions. The company's portfolio includes medications for schizophrenia, depression, alcohol dependence, multiple sclerosis, and bipolar disorder. Alkermes aims to improve the lives of individuals living with CNS disorders through its commitment to research, development, and commercialization.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

75 Patents

#14 in Waltham, MA

#260 in Massachusetts

#4,709 in US

#9,625 in the World

Waltham, MA, United States of America

Alkermes, Inc.

Forward Citations = 2,935

95 inventors:

Juan C Alvarez (11 out of 15 patents)

Steven G Wright (10 out of 42 patents)

J Michael Ramstack (8 out of 44 patents)

4. Joyce M Hotz (8 out of 30 patents)

5. Phillip M Friden (8 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…